GSC Biological and Pharmaceutical Sciences

eISSN: 2581-3250 CODEN (USA): GBPSC2

Cross Ref DOI: 10.30574/gscbps

Journal homepage: https://gsconlinepress.com/journals/gscbps/

(Review Article)

Check for updates

Review on asthma disease and future direction

Komal K Bhagat *, Nitin B Kohale, Suraj K Yadav, Sonam B Bisen and Harigopal S Sawarkar

Department of Pharmaceutics, Dr Rajendra Gode College of Pharmacy Amravati, Dist- Amravati (444602), Maharashtra, India.

GSC Biological and Pharmaceutical Sciences, 2024, 29(02), 231–242

Publication history: Received on 30 September 2024; revised on 15 November 2024; accepted on 18 November 2024

Article DOI: https://doi.org/10.30574/gscbps.2024.29.2.0429

Abstract

Asthma is a chronic respiratory disorder marked by inflammation and obstruction of the airways, resulting in symptoms such as wheezing, breathlessness, chest tightness, and coughing. Affecting over 300 million people globally, asthma is triggered by genetic and environmental factors, including allergens, pollutants, and respiratory infections. While current treatment strategies, including inhaled corticosteroids and bronchodilators, help manage symptoms, asthma remains a significant public health challenge with no definitive cure. Diagnostic approaches rely on clinical assessment and pulmonary function tests. Looking ahead, future directions in asthma research are focused on personalized medicine, targeting the unique genetic and environmental factors that contribute to asthma variability among patients. Innovative treatments such as biologics, which aim to modulate immune pathways involved in inflammation, are showing promise for severe asthma cases. Additionally, advancements in digital health, such as wearable devices and mobile apps, are improving disease monitoring and patient adherence to treatment plans. Continued efforts are needed to address disparities in asthma care and to explore preventive strategies, such as early-life interventions to reduce the development of asthma in high-risk populations.

This Article discusses the key aspects of asthma, current treatment challenges, and emerging research directions aimed at improving management and reducing the global burden of the disease.

Keywords: Asthma; Epidemiology; Etiology; Future Direction

1. Introduction

Millions of people worldwide suffer from asthma, a common chronic respiratory condition characterized by inflammation of the airways, which makes it challenging to diagnose and manage. This condition leads to bronchial hyper responsiveness and intermittent airflow obstruction. The primary symptoms of asthma include coughing, wheezing, and shortness of breath, which can be aggravated by triggers such as viral infections or allergens. Both genetic and environmental factors interact in complex ways, influencing the prevalence and severity of asthma. Despite advances in treatment, disparities in asthma care persist, with different populations having unequal access to diagnosis, treatment, and patient education.

Asthma is often linked to other atopic conditions, such as eczema and hay fever, and commonly develops in childhood.[1][2][3] Its severity can range from mild, occasional symptoms to potentially life-threatening airway obstruction. A definitive diagnosis is made through a combination of the patient's medical history, physical examination, pulmonary function tests, and appropriate laboratory assessments. The primary diagnostic tool is spirometry with a post-bronchodilator response (BDR). Key elements of asthma management include access to fast-acting bronchodilators, regular symptom monitoring, continuous patient education, and the use of controller medications tailored to the severity of the disease. Since the early 1990s, asthma prevalence has been on the rise, with the rate increasing from 34.7

* Corresponding author: Nitin B. Kohale

to 49.4 cases per thousand between 1982 and 1992.[4] By 2019, approximately 262 million people worldwide were affected by asthma, and its global prevalence continues to grow. In children, asthma is more common in boys up until the age of 20, when it affects both genders equally. Differences in childhood asthma may be due to atopy or the fact that boys tend to have smaller airways than girls. [6]

Asthma also has a genetic component, though the specific genes responsible for its inheritance are not yet identified. While there are mechanisms underlying the asthma phenotype that strongly suggest a hereditary link, these mechanisms are complex, as asthma does not follow a simple Mendelian inheritance pattern. It is likely that multiple genes contribute to the development of asthma, with variations in locus heterogeneity and polygenic inheritance leading to its diverse manifestations. Immunoglobulin E (IgE) and atopy antibodies, which target specific antigens or environmental triggers, may worsen the condition. Research has shown a strong correlation between asthma and elevated levels of total IgE in the blood. [7]

Objective

- Recognize the classic asthma symptoms, such as coughing, wheezing, and dyspnea.
- During follow-up visits, evaluate asthma severity, control, and exacerbation risk on a regular basis.
- Collaborate together with members of an interdisciplinary healthcare team to maximize patient treatment for asthma.

2. Epidemiology

Asthma is a common condition that affects approximately 4% of the global population.[8] Its incidence has risen over the past few decades. According to epidemiologic studies by the Centers for Disease Control and Prevention (CDC), the prevalence of asthma in the United States increased from 3.0% in 1970 to 7.8% between 2006 and 2008.[9] Currently, asthma affects 8.1% of adults and 8.4% of children in the U.S.[10,11] It is also a leading cause of emergency room visits, with 1.7 million visits in 2015 alone.[12] Between 2001 and 2016, asthma-related deaths in the U.S. decreased from 15 to 10 per million people. However, asthma mortality remains almost five times higher in adults than in children. Significant racial and gender disparities persist in both asthma morbidity and mortality. Women and non-Hispanic Black individuals are particularly affected, with non-Hispanic Blacks being two to three times more likely to die from asthma than other racial groups.[13]

In terms of pathophysiology, asthma is believed to result from a combination of gene-environment and gene-gene interactions. Key risk factors in its development include exposure to tobacco smoke, air pollution, respiratory viral infections, and obesity. [14,15,16,17] Additionally, genetic factors play a significant role in the condition's onset. A Swedish study found that individuals with a family history of atopic asthma are four times more likely to develop the condition.[18] Further research has also shown that children of asthmatic parents are at a higher risk of developing asthma themselves.[19]

As whole genome sequencing continues to identify new genes, the number of genes associated with asthma is steadily increasing. Epidemiological studies also highlight the frequent co-occurrence of asthma and other upper airway conditions. For instance, over 80% of individuals with asthma report having rhinitis, which is characterized by irritation and inflammation of the nasal mucous membranes. Conversely, 10–40% of people with rhinitis also develop asthma. [20, 21] Those with rhinitis face a threefold increased risk of developing asthma, regardless of whether they are atopic.[22] A study by Linneberg et al. found that sensitization to perennial allergens significantly increases the risk of asthma development in individuals with allergic rhinitis (AR), compared to those exposed to seasonal allergens.[23]



Figure 1 Global Epidemiology of asthma

3. Etiology

3.1. Genetics

The diverse phenotypes of asthma are likely the result of complex interactions between environmental and genetic factors. [24,25] Twin and family studies have demonstrated that heredity plays a significant role in the development of both allergies and asthma,[26] likely through the influence of several genes with moderate effects (i.e., genes associated with relative risks in the range of 1.2–2).[27,28] Genome-wide association studies have identified markers near the ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) and gasdermin B (GSDMB) genes on chromosome 17q21, which encode ORM1-like protein 3 and gasdermin-like protein, as being linked to childhood-onset asthma.[29] Additional genetic correlations with asthma include the IL-1 receptor-like 1 (IL1R1), interleukin-33 (IL33), and a novel susceptibility locus at the IF-inducible protein X (PYHIN1) gene, which is particularly relevant in individuals of African descent.[30] Increased expression of thymic stromal lymphopoietin (TSLP) in the airways is also observed in asthmatic patients. Genetics can influence asthma treatment, as patients with the HSD3B1 genotype are more likely to be resistant to glucocorticoids. Moreover, in Black children, bronchodilator response (BDR) is linked to single-nucleotide polymorphisms in SPATA13-AS1 and PRKG1.[31] Variability in concordance rates among monozygotic twins suggests that environmental factors play a significant role in asthma onset. Environmental exposures, such as secondhand smoke, can influence the effects of specific alleles, as seen in the association between the NAT1 gene and childhood asthma. A study of 983 children found that certain genotypes at the 17q21 locus (GSDMB and ORMDL3) provide both genetic risk and environmental protection against asthma.[32]

3.2. Risk Factors

Risk factors for the development of allergies and asthma in early childhood were explored in a comprehensive literature review conducted as part of the Canadian Healthy Infant Longitudinal Development (CHILD) study, an ongoing national multicenter observational study.[33]

The risk of developing asthma is higher in individuals who were born preterm, before 36 weeks of gestation, during infancy, adolescence, and adulthood. Even among preterm infants who do not experience respiratory issues at birth, researchers suggest that delayed lung development may increase the long-term risk of asthma.[34] Asthma is more common in children whose mothers are 20 years old or younger, and less common in children of mothers aged 30 or older. Maternal diet during pregnancy also plays a crucial role. Researchers believe that vitamin D deficiency can impair immune function, particularly affecting dendritic cells and T regulatory cells, which may contribute to early-life wheezing and asthma. Additionally, vitamin D is important for the development of the embryonic lungs.[35]

Infants and young children who experience wheezing due to viral infections, particularly respiratory syncytial virus (RSV) and human rhinovirus, may be at an increased risk of developing asthma later in life. The risk is further heightened by factors such as obesity, early puberty, and exposure to air pollution in early childhood, especially from combustion byproducts of gas-fired appliances and indoor fires.

The primary risk factors for adult-onset asthma include rhinitis, atopy, occupational exposures, and tobacco smoking. Additionally, studies suggest a slight increase in asthma prevalence among postmenopausal women who are undergoing hormone replacement therapy.

Occupational asthma can be triggered by workplace sensitizers through a latency period, which may involve both low- and high-molecular-weight compounds. High-molecular-weight substances, such as flour, consist of plant or animal-based proteins and polysaccharides, while low-molecular-weight compounds like formaldehyde interact with human proteins to form sensitizing neoantigens. Additionally, occupational asthma can also result from nonallergic, nonimmunological processes caused by exposure to irritants such as gases, fumes, smoke, and aerosols.

3.3. Pathophysiology

T helper cell type-2 (Th2) immune responses, which are also common in other atopic disorders, are strongly associated with asthma. Asthma can be triggered by both non-allergic factors, such as viral infections, tobacco smoke, cold air, and exercise, as well as allergic stimuli, including dust mites, cockroach debris, animal dander, mold, and pollen. These triggers initiate a cascade of events that lead to persistent airway inflammation. Elevated Th2 cell levels in the airways not only promote eosinophilic inflammation and the production of immunoglobulin E (IgE), but also stimulate the release of cytokines such as interleukin (IL)-4, IL-5, IL-9, and IL-13. When IgE production is triggered, inflammatory mediators like histamine and cysteinyl leukotrienes are released, leading to bronchospasm (contraction of airway smooth muscle), edema, and increased mucus production, all of which contribute to the hallmark symptoms of asthma (Global Initiative for Asthma, GINA).[36]

The inflammatory reaction, known as the late-phase asthmatic response, leads to ongoing airway inflammation and bronchial hyperactivity. This process is amplified by the mediators and cytokines produced during the early phase of the immune response to a triggering event.[37]

Frequent asthma flare-ups lead to airway remodeling, a process that gradually worsens airway obstruction and results in a greater decline in lung function over time.[38]



Figure 2 Pathophysiology of Asthma

Figure A shows the location of the lungs and airways in the body. Figure B shows a cross-section of a normal airway. Figure C shows a cross-section of an airway during asthma symptoms.

3.4. Diagnosis

This chart outlines the typical steps and tests that may be used in diagnosing asthma, based on the patient's symptoms, medical history, and additional diagnostic requirements.

Table 1 Diagnosis

Step	Description	Purpose	Examples/Tests
Medical History & Symptoms	Review of symptoms, triggers, and family history	Identify common asthma symptoms and triggers	- Wheezing, shortness of breath, chest tightness, coughing - Allergies, respiratory infections, environmental triggers - Family history of asthma/allergies
Physical Examination	Physical examination of lungs and signs of allergies	Detect respiratory signs and possible allergy indicators	- Listening to lungs for wheezing - Checking for eczema or nasal allergies
Initial Lung Function Test	Measure airflow obstruction and reversibility	Assess baseline lung function and response to medication	- Spirometry: Measures amount and speed of exhaled air - Peak Flow Meter: Measures peak expiratory flow rate
Bronchodilator Reversibility Test	Repeat spirometry after using a bronchodilator	Determine if symptoms improve with medication	- Increased airflow after bronchodilator use may confirm asthma
Additional Testing	Additional tests as needed based on initial findings	Further assess inflammation, sensitivity, and asthma control	- Methacholine Challenge: Tests airway hyperreactivity - FeNO Test: Measures nitric oxide in breath to detect inflammation - Oscillometry: Measures resistance in smaller airways
Imaging (if needed)	Imaging to rule out other conditions	Assess structural lung changes or exclude other diseases	- HRCT or MRI: Used to visualize airways and lung structure
Allergy Testing	Identify potential allergens that trigger symptoms	Detect allergic causes and guide treatment	- Skin prick tests - Blood tests for specific IgE antibodies

The chart above provides a structured approach to diagnosing asthma, starting with an assessment of symptoms and basic lung function tests, and progressing to more advanced or specialized tests as necessary. Each step is designed to confirm the asthma diagnosis or rule out other potential causes, helping to ensure a targeted and effective treatment plan.

3.5. Management and Treatment

The primary goals of asthma treatment are controlling symptoms, preventing flare-ups, and preserving healthy lung function. The management approach is tailored to the phenotype and severity of the asthma. The following are the key components of effective asthma management:

3.5.1. Asthma Medications

Asthma medications are generally classified into two types: long-term control medications and quick-relief (rescue) medications.

Long-term Controller Medications (used daily to prevent symptoms)

- Inhaled Corticosteroids (ICS): These are the most effective long-term medications for reducing airway inflammation.
  - Examples: Budesonide, fluticasone, beclomethasone.
  - Role: First-line treatment for most individuals with persistent asthma.
- Long-Acting Beta-Agonists (LABA): Bronchodilators that help relax airway muscles for up to 12 hours. Typically used in combination with ICS.
  - Examples: Salmeterol, formoterol.
  - Role: LABAs should never be used alone to treat asthma and are always combined with ICS for safety and effectiveness.
- Leukotriene Modifiers: Medications that block the action of leukotrienes, inflammatory chemicals involved in asthma attacks.
  - Examples: Montelukast, zafirlukast.
  - Role: Often used as an alternative or adjunct to ICS, particularly in patients with allergic asthma or aspirin-exacerbated respiratory disease (AERD).
- Biological Therapy: Targeted treatments for severe asthma, especially for specific phenotypes such as eosinophilic asthma or allergic asthma.
  - Examples: Omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5 receptor).
  - Role: Used for severe asthma that is difficult to control with standard medications.
- Theophylline: A less commonly used bronchodilator for long-term asthma control. Requires monitoring for side effects.
  - Role: Can help relax airway muscles but is typically used when other medications are not effective.
- Oral Corticosteroids: Used for short-term treatment of severe or worsening asthma, but not recommended for long-term use due to potential side effects.
  - Role: Used in acute exacerbations or when asthma is poorly controlled despite other treatments.

Quick-Relief (Rescue) Medications (for treating acute symptoms): These medications are used to relieve symptoms during an asthma attack.

- Short-acting beta-agonists (SABA): Provide rapid relief by relaxing bronchial muscles.
  - Examples: Albuterol, Levalbuterol.
  - Action: Used as needed during an asthma attack to relieve symptoms. Not for regular, daily use.
- Anticholinergics: These bronchodilators block specific nerve signals to help relax the airways.
  - Example: Ipratropium bromide.
  - Usage: Sometimes used in combination with SABA when administered via inhaler.
- Oral corticosteroids: Used for short periods to control severe asthma flare-ups.

Asthma Action Plan

Every patient should work with a healthcare provider to create an asthma action plan. This plan includes:

- Daily Management: Taking prescribed medications regularly, monitoring symptoms, and tracking peak flow (and blood pressure, if needed).
- Guidelines for Worsening Symptoms: Instructions on how to adjust medications if symptoms worsen or peak flow decreases.
- Emergency Care: Steps to follow during a severe asthma attack, including when to use over-the-counter medications and when to seek emergency care.
- Peak Flow Monitoring and Follow-Up: For some patients, monitoring peak expiratory flow (PEF) can help detect early signs of asthma worsening.
- Spirometry: Periodic lung function tests (spirometry) are recommended to assess asthma control.
- Symptom Monitoring: Patients should monitor for changes in symptoms, such as increased nighttime coughing, increased use of rescue medications, and other signs of worsening asthma.

Trigger Avoidance:

Identifying and avoiding asthma triggers can significantly reduce symptoms and prevent exacerbations. Common triggers include:

- **Allergens:** Pollen, dust mites, mold, pet dander, and cockroach particles.
- **Irritants:** Smoke, air pollution, strong odors, and certain cleaning products.
- **Respiratory Infections:** Colds, the flu, and sinus infections.
- **Exercise:** For exercise-induced asthma, pre-treatment with a short-acting beta-agonist (SABA) may be recommended.
- **Weather Changes:** Cold air, high humidity, or sudden temperature shifts can exacerbate asthma symptoms.

Modifications in Lifestyle

- **Quitting Smoking:** Smoking and exposure to secondhand smoke can worsen asthma. Quitting smoking is crucial for better asthma management.
- **Exercise:** Regular physical activity can improve overall health and lung function. For individuals with exercise-induced asthma, pre-treatment with a short-acting beta-agonist (SABA) may be necessary before physical activity.
- **Weight Management:** Losing weight can significantly improve asthma control in individuals with obesity-related asthma.
- **Vaccines:** To help prevent respiratory infections that could trigger asthma exacerbations, individuals with asthma should stay up to date with their vaccinations:
- **Influenza Vaccine:** Annual flu vaccination is recommended.
- **Pneumococcal Vaccine:** The pneumococcal vaccine is also important, particularly for individuals at higher risk of respiratory infections.

Managing Intense Asthma

- Early Recognition: Patients should be educated to recognize early warning signs of worsening asthma, such as an increased need for rescue inhalers, nighttime symptoms, or shortness of breath.
- Step-up Therapy: If symptoms worsen, oral corticosteroids and rescue medications (e.g., SABA) may be required.
- Emergency Care: Emergency medical attention is necessary if rescue medications do not relieve symptoms or if peak flow measurements are dangerously low.

Special Consideration for Severe Asthma

- **Additional Therapies:** For individuals with severe asthma who do not respond to conventional treatments, the following options may be considered:
  - **Biologics:** As mentioned earlier, biologic medications such as mepolizumab and omalizumab target specific asthma phenotypes to help control symptoms.
  - **Bronchial Thermoplasty:** This minimally invasive procedure reduces the smooth muscle in the airways, helping to decrease the frequency and severity of asthma attacks.
  - **Referral to Specialists:** In cases of severe asthma, referral to a pulmonologist or asthma specialist may be necessary for advanced care and management.

Education and Self-Control

- **Long-term Control:** Effective long-term asthma management relies on educating patients about their condition, their medications, and the proper use of inhalers.
- **Healthcare Visits:** During medical appointments, self-management strategies are reinforced, and inhaler techniques are routinely reviewed to ensure proper use.

The patient and healthcare provider collaborate to manage asthma effectively, focusing on long-term control, preventing exacerbations, and ensuring high-quality care.

4. Future Directions For Asthma:

Future directions in asthma management and research aim to improve treatment outcomes, enhance patients' quality of life, and potentially discover a cure. Advances in technology, personalized medicine, and a deeper understanding of the underlying mechanisms of asthma are shaping the future of asthma care.

Here are some key areas of development:

4.1. Precision Medicine and Phenotyping

- **Tailored Treatments:** Given that asthma is a heterogeneous disease, research is increasingly focused on personalized treatment approaches based on specific asthma phenotypes and biomarkers. By targeting therapies to the patient’s unique type of asthma (e.g., eosinophilic asthma, allergic asthma), treatment effectiveness is expected to improve.
- **Biomarkers:** Identifying biomarkers, such as blood eosinophil levels, periostin, or fractional exhaled nitric oxide (FeNO), can help guide treatment decisions, enabling more precise and individualized care.

4.2. Advances in Biologic Therapies

- **Next-Generation Biologics:** Current biologic therapies (e.g., anti-IL-5, anti-IL-4, and anti-IgE) have significantly advanced the treatment of severe asthma. Future research is focused on developing new biologics that target additional inflammatory pathways or mechanisms of airway hyperresponsiveness in asthma.
- **Expanded Use of Biologics:** As understanding of asthma phenotypes grows, biologics may be expanded for use in a broader range of asthma types, including non-eosinophilic and non-allergic asthma.
- **Combination Biologics:** Researchers are investigating the potential of combining different biologic therapies to target multiple pathways at once, which could improve outcomes for patients with severe asthma.

4.3. Gene Therapy and CRISPR Technology

- **Gene Therapy:** Research is ongoing to explore whether gene therapy could be used to correct genetic mutations linked to asthma. Although still in the early stages, this approach holds the potential for long-term or even permanent relief from asthma.
- **CRISPR:** The gene-editing technology CRISPR is being investigated as a tool to modify genes that contribute to airway inflammation or hyperresponsiveness. While clinical applications are still far from realization, CRISPR has the potential to revolutionize asthma treatment in th

4.4. Microbiome Research

- **Role of the Microbiome:** Emerging evidence suggests that both the gut and lung microbiomes play a significant role in the development and exacerbation of asthma. Future research is exploring how modifying the microbiome through probiotics, diet, or other interventions—might prevent asthma or reduce its severity.
- **Targeted Probiotics and Prebiotics:** If further research confirms their potential, probiotics and prebiotics could become part of asthma management by helping to modulate immune responses and reduce airway inflammation.

4.5. Improved Inhaler Technology

- **Smart Inhalers:** These devices are equipped with sensors and digital technology to track medication usage and improve adherence. They monitor when and how often patients use their inhalers, providing reminders or feedback to ensure correct usage. Data collected from smart inhalers can also be shared with healthcare providers to inform treatment decisions.
- **More Efficient Drug Delivery:** Future inhalers may be designed to deliver medications more effectively, potentially requiring lower doses and minimizing side effects.

4.6. Environmental Monitoring and Predictive Tools

- **Real-Time Trigger Monitoring:** Wearable technology and smartphone apps, integrated with air quality sensors, may alert patients to environmental conditions (e.g., pollen, pollution, humidity) that could trigger asthma. These tools could provide real-time, personalized recommendations to help patients avoid potential triggers.

- **Artificial Intelligence (AI) and Machine Learning:** AI and machine learning are being explored to predict asthma exacerbations by analyzing patient data, environmental factors, and lifestyle patterns. Predictive models could enable early intervention, potentially preventing asthma attacks.

4.7. Immunotherapy Advances

- **Allergen-Specific Immunotherapy:** Immunotherapy, which involves gradually exposing patients to increasing amounts of allergens to desensitize their immune response, may be enhanced to improve both effectiveness and safety for individuals with allergic asthma. Refinements in subcutaneous and sublingual immunotherapy could lead to better outcomes.
- **Vaccines for Asthma:** Ongoing research is focused on developing vaccines that could prevent or alter the progression of asthma, especially in children with high-risk genetics or early-life exposures.

4.8. Bronchial Thermoplasty Refinements

- **Non-Invasive Alternatives:** Although bronchial thermoplasty, which reduces airway smooth muscle, has shown promise for some patients with severe asthma, researchers are exploring less invasive alternatives that may provide similar benefits.
- **Long-Term Outcomes:** Ongoing research into the long-term effectiveness and safety of bronchial thermoplasty will be crucial in guiding its use and identifying potential improvements to the technique.

4.9. Climate Change and Asthma

- **Understanding Impact:** Research is increasingly focused on how climate change is influencing asthma prevalence and severity. Rising pollen levels, increased pollution, and extreme weather conditions are contributing to worsening asthma outcomes.
- **Mitigation Strategies:** Public health initiatives and policy changes aimed at reducing air pollution and addressing the health effects of climate change may play a central role in asthma management in the future.

4.10. New Anti-Inflammatory Drugs

- **Non-Steroidal Anti-Inflammatories:** Research is focused on developing new anti-inflammatory medications that are not corticosteroids, aiming to reduce the side effects associated with long-term steroid use.
- **Small Molecule Therapies:** These drugs target specific inflammatory pathways involved in asthma and may offer alternative treatment options to biologics or standard therapies.

4.10.1. Asthma Prevention Strategies

- **Early Intervention in Children:** Research is ongoing to prevent asthma development in high-risk children. Strategies include modifying early-life exposures—such as reducing allergen and pollutant exposure, promoting breastfeeding, and potentially using prebiotics or probiotics to support immune system development.
- **Targeting Viral Infections:** Many asthma exacerbations are triggered by viral infections, particularly rhinovirus. Research is focused on developing antiviral treatments or vaccines to prevent virus-induced asthma flare-ups.

4.11. Global Asthma Initiatives

- **Access to Medications:** Efforts are being made to improve access to essential asthma medications in low- and middle-income countries, where asthma care is often inadequate. Global health initiatives aim to reduce the asthma burden by enhancing diagnosis, expanding treatment availability, and increasing patient education.
- **Standardized Guidelines:** The development of universal asthma management guidelines, adapted to different healthcare settings and available resources, is a key focus for improving global asthma outcomes.

In summary, the future of asthma management is shifting toward more personalized, precise treatments, driven by advancements in biologics, gene therapy, technology, and environmental monitoring. These innovations aim to enhance asthma control, reduce exacerbations, and potentially offer long-term solutions for asthma patients.

5. Conclusion

Asthma is a chronic, potentially debilitating respiratory condition that affects millions of people worldwide. Despite advances in treatment, it remains a major public health challenge, contributing to significant morbidity and reducing quality of life. The disease's complex nature, involving genetic, environmental, and lifestyle factors, makes management difficult, as patients often have varying responses to treatment. Current therapies, such as inhalers and biologics, provide symptom control and reduce the frequency of exacerbations, but there is no cure for asthma. Effective long-term management requires consistent adherence to prescribed treatments, awareness of triggers, and ongoing patient education.

In conclusion, while asthma is a manageable condition, effective control requires ongoing research, better therapeutic options, and continued public health efforts to reduce environmental triggers, such as air pollution. The future of asthma care will likely focus on personalized treatment approaches and preventive strategies aimed at improving patient outcomes and quality of life.

Compliance with ethical standards

Disclosure of conflict of interest

No conflict of interest to be disclosed.

References

[1] Lee j, mcdonald c. Review: immunotherapy improves some symptoms and reduces long-term medication use in mild to moderate asthma. Ann intern med. 2018 aug 21;169(4):jc17. [pubmed]

[2] Tesfaye zt, gebreselase nt, horsa ba. Appropriateness of chronic asthma management and medication adherence in patients visiting ambulatory clinic of gondar university hospital: a cross-sectional study. World allergy organ j. 2018;11(1):18. [pmc free article] [pubmed]

[3] Salo pm, cohn rd, zeldin dc. Bedroom allergen exposure beyond house dust mites. Curr allergy asthma rep. 2018 aug 20;18(10):52. [pmc free article] [pubmed]

[4] Dm, homa dm, akinbami lj, moorman je, gwynn c, redd sc. Surveillance for asthma—united states, 1980-1999. Mmwr surveill summ. 2002 mar 29;51(1):1-13. [pubmed]

[5] Mannino dm, homa dm, akinbami lj, moorman je, gwynn c, redd sc. Surveillance for asthma—united states, 1980-1999. Mmwr surveill summ. 2002 mar 29;51(1):1-13. [pubmed])

[6] Weiss st, gold dr. Gender differences in asthma. Pediatr pulmonol. 1995 mar;19(3):153-5. [pubmed]

[7] Burrows b, martinez fd, halonen m, barbee ra, cline mg. Association of asthma with serum ige levels and skin-test reactivity to allergens. N engl j med. 1989 feb 02;320(5):271-7. [pubmed

[8] Bousquet, j.; dahl, r.; khaltaev, n. Global alliance against chronic respiratory diseases. Allergy 2007, 62, 216–223. [google scholar] [crossref]

[9] Loftus, p.a.; wise, s.k. epidemiology and economic burden of asthma. Int. Forum allergy rhinol. 2015, 5 (suppl. 1), s7–s10. [google scholar] [crossref]

[10] Black, l.i.; benson, v. Tables of summary health statistics for u.s. children: 2017; national health interview survey: atlanta, ga, usa, 2018. [google scholar]

[11] Blackwell, d.l.; villarroel, m.a. tables of summary health statistics for u.s. adults: 2017; national health interview survey: atlanta, ga, usa, 2018. [google scholar])

[12] (rui, p.; kang, k. National hospital ambulatory medical care survey: 2015 emergency department summary tables; centers for disease control and prevention: atlanta, ga, usa, 2015. [google scholar]

[13] .(xu, j.; murphy, s.l.; kochanek, k.d.; bastian, b.; arias, e. Deaths: final data for 2016. In national vital statistics reports; centers for disease control and prevention: atlanta, ga, usa, 2018. [google scholar])

[14] Jackson, d.j.; gangnon, r.e.; evans, m.d.; roberg, k.a.; anderson, e.l.; pappas, t.e.; printz, m.c.; lee, w.m.; shult, p.a.; reisdorf, e.; et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care med. 2008, 178, 667–672. [google scholar] [crossref] [pubmed]

[15] Zemp, e.; elsasser, s.; schindler, c.; kunzli, n.; perruchoud, a.p.; domenighetti, g.; medici, t.; ackermann-liebrich, u.; leuenberger, p.; monn, c.; et al. Long-term ambient air pollution and respiratory symptoms in adults (sapaldia study). The sapaldia team. Am. J. Respir. Crit. Care med. 1999, 159 pt 1, 1257–1266. [google scholar] [crossref]

[16] Beuther, d.a.; sutherland, e.r. overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am. J. Respir. Crit. Care med. 2007, 175, 661–666. [google scholar] [crossref] [pubmed])

[17] Lundback, b. Epidemiology of rhinitis and asthma. Clin. Exp. Allergy 1998, 28 (suppl. 2), 3–10. [google scholar

[18] Lim, r.h.; kobzik, l.; dahl, m. Risk for asthma in offspring of asthmatic mothers versus fathers: a meta-analysis. Plos one 2010, 5, e10134. [google scholar] [crossref] [pubmed])

[19] Bousquet, j.; khaltaev, n.; cruz, a.a.; denburg, j.; fokkens, w.j.; togias, a.; zuberbier, t.; baena-cagnani, c.e.; canonica, g.w.; van weel, c.; et al. Organization world health, galen, and allergen. Allergic rhinitis and its impact on asthma (aria) 2008 update (in collaboration with the world health organization, ga(2)len and allergen). Allergy 2008, 63 (suppl. 86), 8–160. [google scholar] [crossref]

[20] Bousquet, j.; van cauwenberge, p.; khaltaev, n. Group aria workshop, and organization world health. Allergic rhinitis and its impact on asthma. J. Allergy clin. Immunol. 2001, 108, s147–s334. [google scholar] [crossref] [pubmed])

[21] Guerra, s.; sherrill, d.l.; martinez, f.d.; barbee, r.a. rhinitis as an independent risk factor for adult-onset asthma. J. Allergy clin. Immunol. 2002, 109, 419–425. [google scholar] [crossref] [pubmed]

[22] Linneberg, a.; nielsen, n.h.; frolund, l.; madsen, f.; dirksen, a.; jorgensen, t.; study copenhagen allergy. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The copenhagen allergy study. Allergy 2002, 57, 1048–1052. [google scholar] [crossref] [pubmed]

[23] Piloni d, tirelli c, domenica rd, conio v, grosso a, ronzoni v, antonacci f, totaro p, corsico ag. Asthma-like symptoms: is it always a pulmonary issue? Multidiscip respir med. 2018;13:21. [pmc free article] [pubmed] aggarwal b, mulgirigama a, berend n. Exercise-induced bronchoconstriction: prevalence, pathophysiology, patient impact, diagnosis and management. Npj prim care respir med. 2018 aug 14;28(1):31. [pmc free article] [pubmed]) fam

[24] Willemsen g, van beijsterveldt tcem, van baal cgcm, et al. Heritability of self-reported asthma and allergy: a study in adult dutch twins, siblings and parents. Twin res hum genet. 2008;11:132–42. [pubmed] [google scholar

[25] Holberg cj, elston rc, halonen m, et al. Segregation analysis of physician-diagnosed asthma in hispanic and non-hispanic white families. A recessive component? Am j respir crit care med. 1996;154:144–50. [pubmed] [google scholar] lawrence s, beasley r, doull i, et al. Genetic analysis of atopy and asthma as quantitative traits and ordered polychromies'. Ann hum genet. 1994;58:359–68. [pubmed] [google scholar]

[26] Gui h, levin am, hu d, sleiman p, xiao s, mak acy, yang m, barczak aj, huntsman s, eng c, hochstadt s, zhang e, whitehouse k, simons s, cabral w, takriti s, abecasis g, blackwell tw, kang hm, nickerson da, germer s, lanfear de, gilliland f, gauderman wj, kumar r, erle dj, martinez fd, hakonarson h, burchard eg, williams lk. Mapping the 17q12-21.1 locus for variants associated with early-onset asthma in african americans. Am j respir crit care med. 2021 feb 15;203(4):424-436. [pmc free article] [pubmed

[27] Torgerson dg, ampleford ej, chiu gy, gauderman wj, gignoux cr, graves pe, himes be, levin am, mathias ra, hancock db, baurley jw, eng c, stern da, celedón jc, rafaels n, capurso d, conti dv, roth la, soto-quiros m, togias a, li x, myers ra, romieu i, van den berg dj, hu d, hansel nn, hernandez rd, israel e, salam mt, galanter j, avila pc, avila l, rodriquez-santana jr, chapela r, rodriguez-cintron w, diette gb, adkinson nf, abel ra, ross kd, shi m, faruque mu, dunston gm, watson hr, mantese vj, ezurum sc, liang l, ruczinski i, ford jg, huntsman s, chung kf, vora h, li x, calhoun wj, castro m, sienra-monge jj, del rio-navarro b, deichmann ka, heinzmann a, wenzel se, busse ww, gern je, lemanske rf, beaty th, bleecker er, raby ba, meyers da, london sj, mexico city childhood asthma study (mcaas). Gilliland fd, children's health study (chs) and harbors study. Burchard eg, genetics of asthma in latino americans (gala) study, study of genes-environment and admixture in latino americans (gala2) and study of african americans, asthma, genes & environments (sage). Martinez fd, childhood asthma research and education (care) network. Weiss st, childhood asthma management program (camp). Williams lk, study of asthma phenotypes and pharmacogenomic interactions by race-ethnicity (sapphire). Barnes kc, genetic research on asthma in african diaspora (graad) study. Ober c, nicolae dl. Meta-analysis of genome-wide association studies of asthma in ethnically diverse north american populations. Nat genet. 2011 jul 31;43(9):887-92. [pmc free article] [pubmed]

[28] Fishe jn, labilloy g, higley r, casey d, ginn a, baskovich b, blake kv. Single nucleotide polymorphisms (snps) in prkg1 & spata13-as1 are associated with bronchodilator response: a pilot study during acute asthma exacerbations in african american children. Pharmacogenet genomics. 2021 sep 01;31(7):146-154. [pmc free article] [pubmed

[29] Loss gj, depner m, hose aj, genuneit j, karvonen am, hyvärinen a, roduit c, kabesch m, lauener r, pfefferle pi, pekkanen j, dalphin jc, riedler j, braun-fahrländer c, von mutius e, ege mj., pasture (protection against allergy study in rural environments) study group. The early development of wheeze. Environmental determinants and genetic susceptibility at 17q21. Am j respir crit care med. 2016 apr 15;193(8):889-97. [pubmed]

[30] Castro-rodriguez ja, forno e, rodriguez-martinez ce, celedón jc. Risk and protective factors for childhood asthma: what is the evidence? J allergy clin immunol pract. 2016 nov-dec;4(6):1111-1122). The incidence of childhood asthma increases with a maternal age of 20 or younger and decreases with a maternal age of 30 or older. Maternal diet during pregnancy holds significance, with researchers suggesting that vitamin d deficiency contributes to early-life wheezing and asthma primarily by impacting the immune function of various cell types, notably dendritic and t regulatory cells. Additionally, vitamin d plays a role in fetal lung development. (wolsk hm, chawes bl, litonjua aa, hollis bw, waage j, stokholm j, bønnelykke k, bisgaard h, weiss st. Prenatal vitamin d supplementation reduces risk of asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled trials. Plos one. 2017;12(10):e0186657.)

[31] Stein rt, martinez fd. Asthma phenotypes in childhood: lessons from an epidemiological approach. Paediatr respir rev. 2004;5(2):155–161. Doi: 10.1016/j.prrv.2004.01.007.